- #1194022
- AbbVie公司#00074210001
SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Prefilled Auto-Injector 1 mL
SKYRIZI, PEN 150MG/ML
Features
- SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Single-Dose Pen
- More …
Container Type
Prefilled Auto-Injector Prefilled SyringeProduct Details Email
Product Specifications
McKesson # | 1194022 |
Manufacturer # | 00074210001 |
Brand | SKYRIZI® |
Manufacturer | AbbVie公司 |
Country of Origin | Germany |
Application | Monoclonal Antibody |
Container Type | Prefilled Auto-Injector |
Dosage Form | Injection |
Generic Drug Name | Risankizumab-rzaa |
NDC Number | 00074210001 |
Product Dating | McKesson Acceptable Dating: we will ship >= 180 days |
Storage Requirements | Requires Refrigeration |
Strength | 150 mg / mL |
Type | Subcutaneous |
UNSPSC Code | 51241200 |
Volume | 1 mL |
Features
- SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Single-Dose Pen
More Information
Professionals Also Viewed
- #1194021
- AbbVie公司#00074105001
- SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
- Single-Dose Prefilled Syringe
- #1212567
- 14
- AbbVie US LLC #00074501501
- SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
- SKYRIZI is indicated for the treatment of active psoriatic arthritis i …
- SKYRIZI is indicated for the treatment of moderately to severely activ …
- # 1212568
- AbbVie US LLC #00074107001
- SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
- SKYRIZI is indicated for the treatment of active psoriatic arthritis i …
- SKYRIZI is indicated for the treatment of moderately to severely activ …
- #1221601
- AbbVie US LLC #0074106501
- SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
- 180 mg/1.2 mL (150 mg/mL) single-dose prefilled cartridge with on-body …